Danielle Brill
Stock Analyst at Truist Financial
Total Price Targets
26
Stocks Covered
18
Sectors
Healthcare
Most Recent
Mar 17, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Danielle Brill
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| CLYM | Climb Bio, Inc. | $17.00 | $8.97 | +89.5% | 1 | Mar 17, 2026 |
| MAZE | Maze Therapeutics, Inc. | $68.00 | $27.23 | +149.7% | 1 | Mar 17, 2026 |
| APGE | Apogee Therapeutics, Inc. | $83.00 | $81.23 | +2.2% | 1 | Mar 17, 2026 |
| BBIO | BridgeBio Pharma, Inc. | $95.00 | $69.25 | +37.2% | 2 | Feb 25, 2026 |
| NBIX | Neurocrine Biosciences, Inc. | $140.00 | $131.64 | +6.4% | 4 | Feb 17, 2026 |
| BIIB | Biogen Inc. | $193.00 | $186.69 | +3.4% | 1 | Feb 9, 2026 |
| INSM | Insmed Incorporated | $205.00 | $133.75 | +53.3% | 2 | Jan 12, 2026 |
| TECX | Tectonic Therapeutic, Inc. | $60.00 | $29.00 | +106.9% | 1 | Jan 8, 2026 |
| DNTH | Dianthus Therapeutics, Inc. | $56.00 | $87.86 | -36.3% | 1 | Oct 14, 2025 |
| PVLA | Palvella Therapeutics, Inc. | $80.00 | $125.87 | -36.4% | 1 | Oct 2, 2025 |
| ALNY | Alnylam Pharmaceuticals, Inc. | $385.00 | $297.62 | +29.4% | 1 | Jul 21, 2025 |
| AGIO | Agios Pharmaceuticals, Inc. | $51.00 | $28.15 | +81.2% | 1 | Oct 31, 2024 |
| RGNX | REGENXBIO Inc. | $18.00 | $9.14 | +96.9% | 1 | Oct 10, 2024 |
| BMRN | BioMarin Pharmaceutical Inc. | $79.00 | $54.20 | +45.8% | 1 | Oct 10, 2024 |
| XENE | Xenon Pharmaceuticals Inc. | $50.00 | $56.81 | -12.0% | 2 | Oct 10, 2024 |
| IRON | Disc Medicine, Inc. | $50.00 | $67.31 | -25.7% | 3 | Aug 8, 2024 |
| HRMY | Harmony Biosciences Holdings, Inc. | $37.00 | $31.74 | +16.6% | 1 | Apr 30, 2024 |
| QURE | uniQure N.V. | $58.00 | $19.21 | +201.8% | 1 | Dec 16, 2021 |
Recent Activity
- Mar 17, 2026— Set$68.00price target onMAZE(Maze Therapeutics, Inc.)
- Mar 17, 2026— Set$83.00price target onAPGE(Apogee Therapeutics, Inc.)
- Mar 17, 2026— Set$17.00price target onCLYM(Climb Bio, Inc.)
- Feb 25, 2026— Set$95.00price target onBBIO(BridgeBio Pharma, Inc.)
- Feb 17, 2026— Set$140.00price target onNBIX(Neurocrine Biosciences, Inc.)
- Feb 9, 2026— Set$193.00price target onBIIB(Biogen Inc.)
- Jan 12, 2026— Set$205.00price target onINSM(Insmed Incorporated)
- Jan 8, 2026— Set$60.00price target onTECX(Tectonic Therapeutic, Inc.)
- Dec 19, 2025— Set$202.00price target onINSM(Insmed Incorporated)
- Oct 29, 2025— Set$172.00price target onNBIX(Neurocrine Biosciences, Inc.)
- Oct 14, 2025— Set$56.00price target onDNTH(Dianthus Therapeutics, Inc.)
- Oct 2, 2025— Set$80.00price target onPVLA(Palvella Therapeutics, Inc.)
- Jul 21, 2025— Set$385.00price target onALNY(Alnylam Pharmaceuticals, Inc.)
- Oct 31, 2024— Set$51.00price target onAGIO(Agios Pharmaceuticals, Inc.)
- Oct 10, 2024— Set$50.00price target onXENE(Xenon Pharmaceuticals Inc.)
- Oct 10, 2024— Set$79.00price target onBMRN(BioMarin Pharmaceutical Inc.)
- Oct 10, 2024— Set$155.00price target onNBIX(Neurocrine Biosciences, Inc.)
- Oct 10, 2024— Set$18.00price target onRGNX(REGENXBIO Inc.)
- Aug 8, 2024— Set$50.00price target onIRON(Disc Medicine, Inc.)
- Jun 24, 2024— Set$46.00price target onBBIO(BridgeBio Pharma, Inc.)
Frequently Asked Questions
Who is Danielle Brill?
Danielle Brill is a stock analyst at Truist Financial covering 18 stocks primarily in Healthcare. They have issued 26 price targets since Dec 16, 2021.
What stocks does Danielle Brill cover?
Danielle Brill currently covers 18 stocks, including NBIX, IRON, BBIO, INSM, XENE.
What is Danielle Brill's latest price target?
Danielle Brill's most recent price target was $68.00 on MAZE (Maze Therapeutics, Inc.), set on Mar 17, 2026.
What is Danielle Brill's highest price target?
Danielle Brill's highest issued price target is $385.00 on ALNY, set on Jul 21, 2025.
More Analysts at Truist Financial
Coverage based on publicly published price targets. Not investment advice.